GO:0072752 cellular response to rapamycin: mTOR Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072752 cellular response to rapamycin describes any process by which a cell changes its state or activity in response to rapamycin, a specific mTOR inhibitor.
• Rapamycin allosterically inhibits mTORC1, leading to dephosphorylation of downstream effectors such as 4E-BP1 and S6K1, which alters translation and autophagy.
• The cellular response to rapamycin includes cell cycle arrest, autophagy induction, and transcriptional reprogramming, with p53/p21 cooperating to enforce G1 arrest.
• MicroRNAs such as miR-218 modulate rapamycin sensitivity by targeting Rictor, linking miRNA networks to the cellular response.
• Mitochondrial genotype and nutrient context can alter the transcriptional response to rapamycin, as shown in Drosophila models.
• Rapamycin's effects on the senescence-associated secretory phenotype (SASP) are mediated by mTOR-regulated IL1A translation, relevant to aging and cancer.
Description
The Gene Ontology (GO) term GO:0072752, cellular response to rapamycin, defines the set of cellular processes triggered when a cell encounters rapamycin, a macrolide compound that inhibits the mechanistic target of rapamycin (mTOR). Rapamycin is widely used experimentally to probe mTOR signaling, and the cellular response encompasses changes in translation, autophagy, cell cycle progression, and gene expression. Understanding this response is critical because mTOR is a central regulator of growth and metabolism, and its inhibition has therapeutic implications in cancer, aging, and metabolic disorders. Researchers studying this term aim to dissect how cells adapt to mTOR inhibition, which often involves feedback loops and context-dependent effects. The response is not uniform; it varies by cell type, genetic background, and nutrient availability, making it a rich area for functional genomics. This article integrates authoritative GO definitions with published literature to provide a research-grade overview of GO:0072752, its molecular players, and experimental approaches.
cellular response to rapamycin At A Glance
| GO ID | GO:0072752 |
|---|---|
| GO term | cellular response to rapamycin |
| Ontology | biological_process |
| Synonym | none |
| Major function | Cellular adaptation to mTOR inhibition by rapamycin, involving translation, autophagy, cell cycle, and transcription |
| Related cellular component | mTORC1 complex, lysosome, cytoplasm |
| Related molecular function | Protein kinase activity, translation initiation factor binding |
| Key upstream regulator | mTOR (mechanistic target of rapamycin) |
| Key downstream effectors | 4E-BP1, S6K1, p53, p21, IL1A |
What Is GO:0072752?
According to the Gene Ontology, GO:0072752 cellular response to rapamycin is defined as any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a rapamycin stimulus. In simpler terms, it is how a cell reacts when exposed to rapamycin, a drug that inhibits mTOR. This response includes alterations in signaling pathways, gene expression programs, and metabolic activities that help the cell cope with or respond to mTOR inhibition.
Why Is cellular response to rapamycin Important in Cell Biology?
The cellular response to rapamycin is important because rapamycin and its analogs are used clinically as immunosuppressants, anti-cancer agents, and potential anti-aging drugs. Understanding how cells respond to rapamycin reveals fundamental mechanisms of mTOR signaling, translation control, and autophagy, which are dysregulated in many diseases. Moreover, the response is highly context-dependent, influenced by genetic and environmental factors, making it a model for personalized medicine. Research on GO:0072752 helps identify biomarkers of rapamycin sensitivity and resistance, and informs combination therapies.
• Rapamycin is a specific allosteric inhibitor of mTORC1, making the cellular response a direct readout of mTORC1 activity.
• The response includes translational reprogramming via 4E-BP1 dephosphorylation and eIF4E sequestration.
• Rapamycin induces autophagy, a process relevant to osteoarthritis and neurodegeneration.
• Cell cycle arrest by rapamycin is enforced by p53/p21, linking the response to tumor suppression.
• MicroRNAs such as miR-218 can modulate rapamycin sensitivity by targeting Rictor.
• Mitochondrial genotype influences the transcriptional response to rapamycin, highlighting gene-environment interactions.
• Rapamycin affects the senescence-associated secretory phenotype by regulating IL1A translation, with implications for aging.
• The response is studied in diverse models from yeast to human cells, providing evolutionary insights.
• Rapamycin response pathways are being explored for therapeutic targeting in cancer and metabolic diseases.
• Understanding the response can guide dosing and patient stratification for rapamycin-based therapies.
What Happens During cellular response to rapamycin?
Inhibition of mTORC1 and Translational Reprogramming
In simple terms: Rapamycin binds to mTORC1 and blocks its ability to promote protein synthesis, causing cells to change which proteins they make.
Rapamycin forms a complex with FKBP12 and allosterically inhibits mTORC1, leading to rapid dephosphorylation of downstream targets such as 4E-BP1 and S6K1. Dephosphorylated 4E-BP1 sequesters eIF4E, reducing cap-dependent translation of growth-related mRNAs. This translational reprogramming is a hallmark of the cellular response to rapamycin and affects proteins involved in proliferation and survival.
Induction of Autophagy
In simple terms: When mTORC1 is blocked, cells increase recycling of their own components through autophagy.
mTORC1 inhibition by rapamycin relieves suppression of autophagy, a catabolic process that degrades damaged organelles and proteins. In osteoarthritis, rapamycin-induced autophagy protects chondrocytes from degeneration, suggesting therapeutic potential. Autophagy induction is a conserved aspect of the cellular response to rapamycin across cell types.
Cell Cycle Arrest
In simple terms: Rapamycin can stop cells from dividing by halting the cell cycle at the G1 phase.
Rapamycin induces G1 cell cycle arrest, and this response is enforced by the p53/p21 pathway. Cells with functional p53 and p21 are more sensitive to rapamycin-induced arrest, determining the cellular outcome. This links the cellular response to rapamycin with tumor suppressor networks.
Transcriptional and microRNA-Mediated Regulation
In simple terms: Cells also change gene expression programs and microRNA levels in response to rapamycin.
Rapamycin alters the transcriptional response to nutrients, with mitochondrial genotype influencing these changes in Drosophila. MicroRNAs such as miR-218 increase cellular sensitivity to rapamycin by targeting Rictor, a component of mTORC2. These layers of regulation fine-tune the cellular response to rapamycin.
Modulation of the Senescence-Associated Secretory Phenotype
In simple terms: Rapamycin affects how senescent cells communicate with their environment by changing the production of inflammatory factors.
mTOR regulates the pro-tumorigenic senescence-associated secretory phenotype (SASP) by promoting IL1A translation, and rapamycin inhibits this process. This links the cellular response to rapamycin with aging and cancer biology.
Key Genes Involved in GO:0072752 cellular response to rapamycin
The following genes and proteins are central to the cellular response to rapamycin, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MTOR | Target of rapamycin; central kinase in mTORC1 and mTORC2 | Primary target; mutations alter rapamycin sensitivity |
| RPTOR | Scaffold protein of mTORC1 | Essential for mTORC1 assembly and rapamycin response |
| RICTOR | Scaffold protein of mTORC2 | Targeted by miR-218; modulates rapamycin sensitivity |
| EIF4EBP1 | 4E-BP1; inhibits translation when dephosphorylated | Key effector of rapamycin-induced translation block |
| RPS6KB1 | S6K1; promotes translation when active | Dephosphorylated upon rapamycin treatment |
| EIF4E | Cap-binding translation initiation factor | Sequestrated by 4E-BP1 upon rapamycin |
| TP53 | p53; tumor suppressor | Cooperates with p21 to enforce rapamycin-induced G1 arrest |
| CDKN1A | p21; cyclin-dependent kinase inhibitor | Mediates cell cycle arrest in response to rapamycin |
| IL1A | Interleukin-1 alpha | Translationally regulated by mTOR; affects SASP |
| MIR218 | MicroRNA-218 | Targets Rictor; increases rapamycin sensitivity |
| FKBP1A | FKBP12; rapamycin-binding protein | Forms complex with rapamycin to inhibit mTOR |
| ULK1 | Autophagy-initiating kinase | Activated upon mTORC1 inhibition by rapamycin |
| BECN1 | Beclin-1; autophagy regulator | Involved in rapamycin-induced autophagy |
| MAP1LC3B | LC3B; autophagosome marker | Monitors autophagic flux in rapamycin response |
| SQSTM1 | p62; autophagy receptor | Degraded during rapamycin-induced autophagy |
| AKT1 | Protein kinase B | Upstream of mTOR; feedback regulation |
| TSC1 | Tuberous sclerosis 1 | Regulates mTORC1 activity upstream of rapamycin |
| TSC2 | Tuberous sclerosis 2 | Regulates mTORC1 activity upstream of rapamycin |
How Is cellular response to rapamycin Regulated?
The cellular response to rapamycin is regulated at multiple levels. The primary target, mTORC1, is controlled by upstream signals including growth factors, amino acids, and energy status via the TSC1/TSC2 complex and Rheb. Rapamycin binding to FKBP12 allosterically inhibits mTORC1 kinase activity, but the extent and duration of inhibition vary by cell type and context. Feedback loops from S6K1 to IRS-1 can modulate the response, and mTORC2 activity may be affected in some settings. MicroRNAs such as miR-218 can target Rictor to enhance rapamycin sensitivity. Additionally, mitochondrial genotype and nutrient availability influence the transcriptional response to rapamycin, as demonstrated in Drosophila. These regulatory layers determine the cellular outcome of rapamycin exposure.
cellular response to rapamycin and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MTOR | Cancer, aging | Knockout or point mutation in cancer cell lines |
| TP53 | Cancer, cell cycle arrest | Knockout in HCT116 or MCF7 cells |
| CDKN1A | Cancer, cell cycle arrest | Knockout in p53-wildtype cells |
| MIR218 | Cervical cancer, rapamycin sensitivity | Overexpression or knockout in HeLa cells |
| IL1A | SASP, aging | Knock-in of tagged IL1A in senescent fibroblasts |
Cancer
Rapamycin and its analogs are used in cancer therapy, and the cellular response to rapamycin determines sensitivity or resistance. mTOR regulates the pro-tumorigenic SASP by promoting IL1A translation, and rapamycin inhibits this process, potentially reducing tumor-promoting inflammation. p53/p21 status affects rapamycin-induced G1 arrest, with loss of p53 leading to resistance. MicroRNA-218 increases rapamycin sensitivity in cervical cancer by targeting Rictor, suggesting miRNA-based strategies to overcome resistance.
Osteoarthritis
Autophagy is impaired in osteoarthritis, and rapamycin-induced autophagy protects chondrocytes from degeneration. The cellular response to rapamycin in joint cells may therefore have therapeutic potential for osteoarthritis.
Aging and Age-Related Diseases
Rapamycin extends lifespan in model organisms, partly through inhibition of the SASP and enhancement of autophagy. The cellular response to rapamycin in senescent cells reduces secretion of inflammatory cytokines, which may delay age-related pathologies.
Metabolic Disorders
mTOR signaling is dysregulated in obesity and diabetes, and rapamycin modulates the cellular response to nutrients. Mitochondrial genotype influences the transcriptional response to rapamycin, highlighting personalized effects.
From cellular response to rapamycin-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X affect rapamycin-induced cell cycle arrest? | CRISPR knockout of gene X in p53-wildtype cell line, followed by rapamycin treatment and flow cytometry |
| Does a point mutation in mTOR alter rapamycin sensitivity? | CRISPR point mutation knock-in of mTOR mutation in HEK293T cells |
| Does gene Y regulate autophagy upon rapamycin treatment? | CRISPR knockout of gene Y in U2OS cells, with LC3B reporter and rapamycin treatment |
| Does overexpression of miR-218 enhance rapamycin sensitivity? | Lentiviral overexpression of miR-218 in cervical cancer cells, followed by rapamycin dose-response |
| Does tagged IL1A show altered translation upon rapamycin? | CRISPR knock-in of HA-tag at IL1A locus in senescent fibroblasts, polysome profiling |
| Does mitochondrial genotype influence rapamycin transcriptional response? | CRISPR knockout of mitochondrial genes in Drosophila S2 cells, RNA-seq after rapamycin |
How to Study the cellular response to rapamycin Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Transcriptional response to rapamycin in various cell types |
| Ribo-seq | Translated mRNA populations | Translational reprogramming by rapamycin |
| Polysome profiling | mRNA association with ribosomes | 4E-BP1-mediated translation inhibition |
| Western blot | Protein phosphorylation and abundance | mTORC1 targets (p-S6K1, p-4E-BP1) |
| LC3B flux assay | Autophagosome formation and degradation | Rapamycin-induced autophagy |
| Flow cytometry | Cell cycle distribution | G1 arrest by rapamycin |
| Luciferase reporter | miRNA target regulation | miR-218 targeting of Rictor |
| Immunofluorescence | Subcellular localization | eIF4E sequestration by 4E-BP1 |
Transcriptomic Profiling
RNA-seq is used to measure global changes in gene expression upon rapamycin treatment, revealing transcriptional programs and alternative splicing events. This method can identify novel regulators and biomarkers of the cellular response to rapamycin.
Translational Profiling
Polysome profiling and Ribo-seq measure changes in translation efficiency, such as 4E-BP1-mediated eIF4E sequestration, which is a key event in the rapamycin response. These techniques can uncover mRNAs whose translation is selectively affected by mTOR inhibition.
Autophagy Flux Assays
LC3B lipidation and p62 degradation are monitored by western blot or fluorescence microscopy to assess autophagic flux induced by rapamycin. These assays are critical for studying the role of autophagy in the cellular response.
Cell Cycle Analysis
Flow cytometry with DNA staining (e.g., propidium iodide) quantifies G1 arrest induced by rapamycin, and can be combined with p53/p21 staining to dissect pathways.
How CRISPR Can Be Used to Study GO:0072752 cellular response to rapamycin
Knockout
CRISPR knockout is used to delete genes such as TP53, CDKN1A, or RICTOR to determine their requirement for the cellular response to rapamycin. For example, p53 knockout abolishes rapamycin-induced G1 arrest, confirming its role.
Point Mutation
Point mutations can be introduced into MTOR or other genes to mimic clinical mutations or to study specific phosphorylation sites. For instance, a point mutation in the FKBP12-binding domain of mTOR can confer rapamycin resistance.
Knock-in
Knock-in of tags (e.g., HA, GFP) at endogenous loci allows visualization and immunoprecipitation of proteins such as IL1A or 4E-BP1 under rapamycin treatment. This enables precise tracking of translation and localization.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression is used to overexpress genes like MIR218 or RICTOR to test their impact on rapamycin sensitivity. Overexpression of miR-218 increases sensitivity to rapamycin in cervical cancer cells.
How EDITGENE Supports cellular response to rapamycin Research
Researchers studying cellular response to rapamycin-related genes often need to determine whether a candidate gene is causally involved in the response or merely correlated. EDITGENE provides comprehensive CRISPR-based services to enable such functional studies, from knockout to precise point mutations and knock-ins, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for cellular response to rapamycin research.
Frequently Asked Questions About cellular response to rapamycin
What is GO:0072752 cellular response to rapamycin?
GO:0072752 is a Gene Ontology term describing any cellular process that changes in response to rapamycin, an mTOR inhibitor. It includes alterations in translation, autophagy, cell cycle, and gene expression.
What genes are involved in the cellular response to rapamycin?
Key genes include MTOR, RPTOR, RICTOR, EIF4EBP1, RPS6KB1, TP53, CDKN1A, and MIR218, among others.
How does rapamycin affect cell cycle progression?
Rapamycin induces G1 arrest through p53/p21-dependent mechanisms, as shown in cancer cell lines.
What is the role of autophagy in the cellular response to rapamycin?
Rapamycin induces autophagy by inhibiting mTORC1, which relieves suppression of ULK1 and other autophagy regulators.
How do microRNAs regulate rapamycin sensitivity?
MicroRNAs such as miR-218 can target Rictor to increase cellular sensitivity to rapamycin.
Does mitochondrial genotype affect the response to rapamycin?
Yes, mitochondrial genotype alters the transcriptional response to nutrients and rapamycin in Drosophila.
What methods are used to study cellular response to rapamycin?
Common methods include RNA-seq, Ribo-seq, polysome profiling, western blot for mTOR targets, autophagy flux assays, and flow cytometry.
How does rapamycin affect the senescence-associated secretory phenotype?
Rapamycin inhibits mTOR-dependent IL1A translation, thereby reducing the pro-tumorigenic SASP.
Can CRISPR be used to study rapamycin response genes?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are powerful tools to dissect gene function in the rapamycin response.
What diseases are linked to the cellular response to rapamycin?
Cancer, osteoarthritis, aging, and metabolic disorders are among the conditions where rapamycin response pathways play a role.
Conclusion
The cellular response to rapamycin (GO:0072752) is a complex biological process centered on mTORC1 inhibition, with far-reaching effects on translation, autophagy, cell cycle, and transcription. Understanding this response is crucial for optimizing rapamycin-based therapies and identifying biomarkers of sensitivity. CRISPR-based functional genomics, combined with multi-omics profiling, offers powerful approaches to dissect the underlying mechanisms. EDITGENE provides end-to-end services to support such research, from knockout to library screening.
References
- 1. Laberge RM et al.. 2015. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation.. Nat Cell Biol 17(8):1049-61 PMID: 26147250
- 2. Totary-Jain H et al.. 2013. MicroRNAs and the cellular response to rapamycin: potential role in diagnosis and therapy.. Cell Cycle 12(6):861-2 PMID: 23442794
- 3. Li YS et al.. 2016. Autophagy in osteoarthritis.. Joint Bone Spine 83(2):143-8 PMID: 26453105
- 4. Li J et al.. 2015. MicroRNA-218 increases cellular sensitivity to Rapamycin via targeting Rictor in cervical cancer.. APMIS 123(7):562-70 PMID: 25908215
- 5. Batool A et al.. 2019. Eukaryotic Initiation Factor 4E (eIF4E) sequestration mediates 4E-BP1 response to rapamycin.. Int J Biol Macromol 125:651-659 PMID: 30552925
- 7. Santiago JC et al.. 2021. Mitochondrial genotype alters the impact of rapamycin on the transcriptional response to nutrients in Drosophila.. BMC Genomics 22(1):213 PMID: 33761878
- 8. Huang S et al.. 2001. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin.. Cancer Res 61(8):3373-81 PMID: 11309295
